Single-fraction stereotactic ablative body radiation therapy for primary and metastasic lung tumor: A new paradigm?

doi:10.5306/wjco.v13.i2.101

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 2

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8494)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-5) series.

Item

Count

PDF

347

WORD

HTML

5712

Figures (1-1)

317

Tables (1-5)

307

Sum=6770

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

222

Download

613

Sum=835

Publishing Process of This Article

Item

Count

Browse

347

Download

542

Sum=889

Feb 24, 2022 (publication date) through Nov 26, 2024

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Clin Oncol. Feb 24, 2022; 13(2): 101-115
Published online Feb 24, 2022. doi: 10.5306/wjco.v13.i2.101

Table 5 Summary of indications for stereotactic ablative body radiotherapy in pandemic COVID-19 in patients with early stage non-small cell lung cancer

ESTRO-ASTRO	UK	GOECP/SEOR
45-54 Gy in 3 fx, 48 Gy in 4 fx; Maximum hypofractionation supported, 30-34 Gy in 1 fx (90% support if choosing hypofractionation)	Safe zone: 34 Gy in 1 fx	Safe zone: 30-34 Gy, 1 fx (first option); 54 Gy in 3 fx
	Tumours within 2.5 cm of the Chest Wall: 48-54 Gy in 3 fx	Safe zone: 30-34 Gy, 1 fx (first option); 54 Gy in 3 fx
	Tumours within 2.5 cm of the Chest Wall: 48-54 Gy in 3 fx	Peripheral lesions: 48 Gy in 4 fx (first option)
	Moderately central: 50 Gy in 5 fx	Peripheral lesions: 48 Gy in 4 fx (first option)
	Moderately central: 50 Gy in 5 fx	Central tumour: 50-60 Gy in 5 fx, 60 Gy in 8 fx
	Ultra-central: 45-50 Gy in 4-5 fx, 60 Gy in 8 fx
	Central/ultra-central early stage tumours not suitable for stereotactic ablative radiotherapy: 50-60 Gy in 15 fx

ESTRO: European Society for Radiotherapy and Oncology; ASTRO: American Society for Radiation Oncology; GOECP: Oncologic Group for the Study of Lung Cancer; SEOR: Spanish Society of Radiation Oncology; UK: United Kingdom.

Citation: Fernández C, Navarro-Martin A, Bobo A, Cabrera-Rodriguez J, Calvo P, Chicas-Sett R, Luna J, Rodríguez de Dios N, Couñago F. Single-fraction stereotactic ablative body radiation therapy for primary and metastasic lung tumor: A new paradigm? World J Clin Oncol 2022; 13(2): 101-115
URL: https://www.wjgnet.com/2218-4333/full/v13/i2/101.htm
DOI: https://dx.doi.org/10.5306/wjco.v13.i2.101